# Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

> **NCT01606800** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 45 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** PEG-IFN alfa-2b
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01606800
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01-01
- **Primary completion:** 2015-01-26
- **Final completion:** 2015-01-26
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** The trial was terminated due to change in new standard of therapy during the study period.
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606800, "Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01606800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*